Search
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalIt is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalcompared to standard VRd therapy. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalBoth T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).
Delorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIn addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy. … Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting.
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedSensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.